BioMed Research International

Novel Approach to the Treatment in Rheumatic Diseases: From Molecule to Value for Patient


Status
Published

Lead Editor

1Poznan University of Medical Sciences, Poznań, Poland

2Pomeranian Medical University, Szczecin, Poland

3Poznan University of Medical Sciences, Poznan, Poland


Novel Approach to the Treatment in Rheumatic Diseases: From Molecule to Value for Patient

Description

Complex inflammatory rheumatic diseases are a very heterogeneous group sometimes not only with joint inflammation but also with a wide variety of extra-articular manifestations involving ocular, gastrointestinal, vascular, metabolic, urogenital, and neuropsychiatric symptoms.

Pathophysiology of rheumatic diseases has an immune-mediated chronic inflammatory origin associated with impaired physical function and reduced quality of life also. The mechanisms of the occurrence of the symptoms are very complicated and have multiway activity and consequences.

The treatment of the diseases is still inefficient. It should include immunology agent treatment as well as physiotherapy and psychotherapy.

In rheumatic diseases therapy, conventional disease-modifying antirheumatic drugs (cDMARD) are commonly used in newly diagnosed ones from 20 years. Data from large, well-designed clinical trial papers show that methotrexate, leflunomide, and sulfasalazine are still regarded as first-choice treatment as well as therapy with nonsteroidal anti-inflammatory drugs (NSAIDs).

Biologic treatment has revolutionized treatment in rheumatology in the last decades meaningfully. With the advent of biological DMARDs (bDMARD), there was a shift in disease effective management with initially improved symptoms and disease control in severe arthritis, followed by a treatment model aimed at disease remission.

Novel treatment strategies by a treat to target approach in rheumatic diseases have aimed at reducing disease activity, improving functional outcome, and better quality of life.

The editors invite authors to present overview of the complexity of rheumatic diseases, looking at several aspects of these such as pathophysiology, important clinical features, and comorbidities as well as current immunology concepts of the and subsequent insights in novel treatment targets including treat to target strategy.

Potential topics include but are not limited to the following:

  • Novel molecules dedicated to the immune system balance restoration
  • New bDMARDs and their mechanisms of action used in rheumatic diseases
  • Monotherapy or biotherapy in rheumatic diseases
  • Complementary therapy
  • Value for patient, new approach to the therapy of rheumatic diseases

Articles

  • Special Issue
  • - Volume 2018
  • - Article ID 3495782
  • - Editorial

Novel Approach to the Treatment in Rheumatic Diseases: From Molecule to Value for Patient

Ewa Mojs | Marek Brzosko | Wlodzimierz Samborski
  • Special Issue
  • - Volume 2018
  • - Article ID 9026357
  • - Research Article

Investigation of MicroRNA in Mitochondrial Apoptotic Pathway in Systemic Lupus Erythematosus

Yu-Jih Su | Nai-Wen Tsai | ... | Cheng-Hsien Lu
  • Special Issue
  • - Volume 2018
  • - Article ID 1042576
  • - Review Article

Efficacy of Spa Therapy, Mud-Pack Therapy, Balneotherapy, and Mud-Bath Therapy in the Management of Knee Osteoarthritis. A Systematic Review

Antonio Fraioli | Gioacchino Mennuni | ... | Angelo Serio
  • Special Issue
  • - Volume 2018
  • - Article ID 7492904
  • - Review Article

Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?

Przemyslaw J. Kotyla
  • Special Issue
  • - Volume 2018
  • - Article ID 7458361
  • - Research Article

Area of Residence and Socioeconomic Factors Reduce Access to Biologics for Rheumatoid Arthritis Patients in Romania

Cătălin Codreanu | Claudiu C. Popescu | Corina Mogoşan
  • Special Issue
  • - Volume 2018
  • - Article ID 3458439
  • - Research Article

Polymorphisms in the Osteopontin Are Associated with Susceptibility to Ankylosing Spondylitis in a Han Chinese Population

Juyi Li | Yi Cai | ... | Guoliang Yang
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit